Ovchinnov 2015.

Methods	Randomised parallel‐group placebo‐controlled trial 12 weeks duration
Participants	Inclusion criteria: Participants with HFpEF (diagnosed by the ESC algorithm, 2007) Reactive pulmonary hypertension (systolic pulmonary artery pressure ≥ 35 mmHg at rest and Doppler‐derived pulmonary vascular resistance > 3.0 units Wood) On standard CHF therapy (WHO Group 2) n = 50
Interventions	Sildenafil (25 mg 3 times a day for 12 weeks followed by 50 mg 3e times a day for 12 weeks; n = 30) or to control group (no sildenafil, n = 20)
Outcomes	6MWD Cycle ergometer exercise duration Systolic pulmonary artery pressure RV function assessed by tricuspid annular systolic excursion Left‐sided diastolic function (E/é ratio)
Notes	Quantitative outcomes were only reported for the sildenafil group; the trial reported "no improvement in control group was observed" so this trial was unable to be included in the meta‐analysis We tried to contact all authors, but at the time of this review publication there has been no reply, or contact details were unavailable Funding source not stated Location and dates not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Paper states participants were randomly assigned, but no methods were given
Allocation concealment (selection bias)	High risk	Compared sildenafil to "no sildenafil" ‐ unclear if placebo was used
Blinding of participants and personnel (performance bias) All outcomes	High risk	Unclear if placebo was used or if participants were blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome assessors were blinded
Incomplete outcome data (attrition bias) All outcomes	High risk	Number of completers were not reported. Mortality or loss to follow‐up were not reported. Methods using intention‐to‐treat or per‐protocol analysis was not specified
Selective reporting (reporting bias)	High risk	Quantitative outcome data were only reported for the sildenafil group, not placebo group, and no P values between groups were reported
Other bias	Unclear risk	Not clear if other bias is possible ‐ abstract from conference proceedings with limited data presented